Exploring Time Off Treatment with a BCL-2 Inhibitor ~ Thursday, Nov 7thSocial Media CoordinatorOct 31, 20241 min readClick here to learn more and register!Abbvie Educational Event November 7 2024.pdfDownload PDF • 7.52MB
CAR-Therapy Adverse Reaction Identification and Management Considerations ~ Thursday, June 12th @ Davio's
NEW EVENT: Exploring the Role of NUBEQA (darolutamide) in mHSPC in Combination with Docetaxel and in nmCRPC PP-NUM-US-3389-1
Comments